COVID-19 Study Finds Promising Drug Target and Inhibitors Using Rattlesnake Venom Peptide

Research from the Institute of Biological Information Processing in Julich, Germany, has identified the 3C-like protease (3CL[superscript]pro) as a vital component in the life cycle of SARS-CoV-2, making it a promising drug target. The study discovered that a cationic peptide from rattlesnake venom, known as crotamine, can be used as a scaffold to design novel biopharmaceutical products that inhibit the 3CL protease. This research has led to the development of D-peptide-based drugs, such as D-CDP, which exhibit potent inhibition of the 3CL protease and have the potential to impair SARS-CoV-2 replication in vivo.

Key Takeaways:

• The 3C-like protease (3CL[superscript]pro) is essential for the life cycle of SARS-CoV-2 and serves as a promising drug target.
• Crotamine, a peptide from rattlesnake venom, exhibits activities such as analgesic, in vitro antibacterial, and hemolytic activities, making it a suitable scaffold for designing novel biopharmaceutical products.
• The crotamine derivative L-peptides (L-CDP) that inhibit the 3CL protease in the low M range were examined, and their D-enantiomers (D-CDP) were found to be more stable and potent inhibitors.
• Comparative uptake inhibition analysis showed D-CDP as a promising prototype for a D-peptide-based drug.
• The D-peptides can impair SARS-CoV-2 replication in vivo, probably targeting the viral protease 3CL[superscript]pro.
• This research has significant implications for the development of new treatments against COVID-19 and highlights the potential of using peptides derived from venom as a basis for drug design.
• The study was conducted by a team of researchers led by Raphael J. Eberle, Ian Gering, Markus Tusche, and Philipp N. Ostermann, among others, from the Institute of Biological Research Information Processing (IBI-7: Structural Biochemistry) at the Forschungszentrum Julich.

Statistics:

• The 3CL protease is inhibited by D-CDP in the low M range.
• The D-peptides showed impairment of SARS-CoV-2 replication in vivo, with a potential EC50 value.
• The study used a comparative uptake inhibition analysis to assess the potency of D-CDP against L-CDP.
• The crotamine peptide was found to have a molecular weight of approximately 3,000 Da.
• The study was published in the journal Pharmaceuticals, Volume 15, Issue 540, in 2022.

Sources:

• Design of D-Amino Acids SARS-CoV-2 Main Protease Inhibitors Using the Cationic Peptide from Rattlesnake Venom as a Scaffold. Pharmaceuticals, 2022, 15(540):540.
• Institute of Biological Information Processing, Julich, Germany, Europe.